- Previous Close
5,844.60 - Open
5,812.00 - Bid --
- Ask --
- Day's Range
5,765.00 - 5,915.00 - 52 Week Range
4,902.00 - 10,524.95 - Volume
18,644 - Avg. Volume
28,129 - Market Cap (intraday)
135.327B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
43.15 - EPS (TTM)
136.18 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield 117.00 (2.00%)
- Ex-Dividend Date Apr 25, 2025
- 1y Target Est
6,672.33
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
www.sanofi.com/en/india/investors--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SANOFI.NS
View MorePerformance Overview: SANOFI.NS
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SANOFI.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SANOFI.NS
View MoreValuation Measures
Market Cap
134.46B
Enterprise Value
131.26B
Trailing P/E
42.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.69
Price/Book (mrq)
15.64
Enterprise Value/Revenue
6.52
Enterprise Value/EBITDA
27.86
Financial Highlights
Profitability and Income Statement
Profit Margin
20.53%
Return on Assets (ttm)
17.06%
Return on Equity (ttm)
33.45%
Revenue (ttm)
20.13B
Net Income Avi to Common (ttm)
3.14B
Diluted EPS (ttm)
136.18
Balance Sheet and Cash Flow
Total Cash (mrq)
2.95B
Total Debt/Equity (mrq)
2.24%
Levered Free Cash Flow (ttm)
3.75B